Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry

Inclusion Criteria: * Patient is newly diagnosed with Peripheral T-cell Lymphoma (PTCL): * Aggressive natural killer (NK)-cell leukemia * Adult T-cell lymphoma/leukemia (human T-cell leukemia virus \[HTLV\] 1+) * Angioimmunoblastic T-cell lymphoma * Anaplastic large cell lymphoma (ALCL), primary systemic type (ALK+, ALK-) * PTCL, not otherwise specified (NOS) * T/NK-cell lymphoma, nasal type * Enteropathy-type intestinal lymphoma * Hepatosplenic T-cell lymphoma * Subcutaneous panniculitis T-cell lymphoma * Transformed mycosis fungoides (at diagnosis of transformation) * T-cell prolymphocytic leukemia (T-PLL) * Cutaneous gamma/delta (γ/δ) T-cell lymphoma * Cutaneous aggressive CD8+ T-cell lymphoma * Hematodermic neoplasms (blastic plasmacytoid dendritic cell neoplasm) * Systemic Epstein Barr Virus (EBV)+ T-cell lymphomas (T-cell lymphoproliferative disorders of childhood) * Other T-Cell lymphomas that are not listed in the Exclusion Criteria * Patient gives written informed consent Exclusion Criteria: * Patient has other T- or NK-cell malignancies including: * Precursor T/NK neoplasms * T-cell large granular lymphocytic leukemia * Mycosis fungoides, other than transformed mycosis fungoides * Sézary syndrome * Primary cutaneous CD30+ disorders: ALCL and lymphomatoid papulosis